Article metrics

Download PDFPDF
559 Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC)

 

Online download statistics by month:

Online download statistics by month: March 2024 to November 2024

AbstractFullPdf
Mar 202414001
Apr 20246403
May 20245500
Jun 20242400
Jul 20243600
Aug 20244100
Sep 20244600
Oct 202411501
Nov 20248000
Total60105